NIH grants Spring Bank $3.9M to develop hepatitis B drug

The National Institute of Allergy and Infectious Diseases awarded Spring Bank Pharmaceuticals a five-year grant worth $3.9 million to advance development of SB 9200, an investigational oral drug for hepatitis B. This is the fourth federal grant supporting the drugmaker's small nucleic acid hybrid technology, bringing the total to more than $12 million. Mass High Tech (Boston)

Source: AABBsmartbrief